Group 1 - The largest shareholder of Chuangye Huikang, Ge Hang, is planning to change the company's status from having no actual controller to having one, which may impact control over the company [1] - Chuangye Huikang's stock was suspended from trading starting November 10, 2025, with an expected suspension period of no more than two trading days [1] - Prior to the suspension, the stock price surged by 7% on November 7, 2025, closing at 5.18 yuan per share with a trading volume of 674 million yuan [3] Group 2 - Chuangye Huikang has been experiencing financial difficulties, reporting a revenue of 1.423 billion yuan in 2024, a year-on-year decrease of 11.96%, and a net loss of 174 million yuan, also a decline of 11.96% [3] - For the first three quarters of 2025, the company reported a revenue of 862 million yuan, down 26.26% year-on-year, and a net loss of 122 million yuan, with a significant decline of 331.69% [3] - The company faced a quarterly loss of 41.67 million yuan in Q3 2025, with revenue dropping by 35.5% year-on-year [3] Group 3 - Multiple major shareholders have been reducing their stakes in Chuangye Huikang, with Ge Hang planning to sell up to 37.038 million shares between October 23, 2025, and January 22, 2026, representing approximately 2.40% of the total share capital [3] - Ge Hang previously reduced his holdings by 9.2947 million shares from July to September 2025, accounting for 0.6018% of the shares [4] - Philips, the second-largest shareholder, also announced plans to reduce its stake by up to 46.3328 million shares from August 27 to November 26, 2025, which is about 3% of the total share capital [4]

Core Points - The company, Chuangye Huikang, announced that its largest shareholder, Ge Hang, who holds over 5% of the shares, is in discussions with Hangzhou Genghao Zhito Management Consulting Partnership regarding control-related matters [1] - This potential change may result in the company transitioning from having no actual controller to having one [1] - As a result of this announcement, the company has applied to the Shenzhen Stock Exchange for a trading suspension, effective from November 10, 2025, with an expected duration of no more than 2 days [1]

每经AI快讯，创业慧康（300451）11月10日公告，公司第一大股东、持股5%以上股东葛航正与杭州更 好智投管理咨询合伙企业(有限合伙)筹划控制权相关事宜，该事项可能导致公司将由无实际控制人状态 变更为有实际控制人状态。经公司向深圳证券交易所申请，公司股票自2025年11月10日(星期一)开市起 停牌，预计停牌时间不超过2个交易日。 ...

北京商报讯（记者 丁宁）11月10日午间，华检医疗（01931.HK）在港交所公告称，公司下属企业出资 设立的有限合伙企业杭州更好智投管理咨询合伙企业（有限合伙），目前正在与创业慧康第一大股东葛 航筹划创业慧康控制权相关事宜。 华检医疗表示，截至公告日期，各方主体仍就可能交易的具体方案（包括但不限于交易结构、代价、时 间表及先决条件）进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可 作实。 ...

Core Viewpoint - Huajian Medical (01931) is in discussions regarding a potential control transaction involving Chuangye Huikang Technology Co., Ltd. (Chuangye Huikang) and its largest shareholder, Ge Hang [1] Group 1: Company Information - Huajian Medical has established a limited partnership enterprise in China, named Hangzhou Genghao Zhito Management Consulting Partnership (Limited Partnership), funded by its subsidiary [1] - Chuangye Huikang is a joint-stock company registered in China, listed on the Shenzhen Stock Exchange's ChiNext board [1] Group 2: Transaction Details - As of the date of the announcement, all parties are still discussing the specific terms of the potential transaction, including but not limited to transaction structure, cost, timeline, and preconditions [1] - The final terms of the potential transaction will require further negotiations and the signing of a formal agreement among the relevant parties [1]

华检医疗(01931)发布公告，公司一家于中国境内设立的有限合伙企业，杭州更好智投管理咨询合伙企 业(有限合伙)(该企业由公司下属企业出资设立，并依照中国法律组建及存续)，目前正在与创业慧康 （300451）科技股份有限公司(创业慧康)第一大股东葛航先生筹划创业慧康控制权相关事宜(可能交 易)。创业慧康(股份代号：300451.SZ)为一间于中国注册成立的股份有限公司，其股份于深圳证券交易 所创业板上市。 截至本公告日期，各方主体仍就可能交易的具体方案(包括但不限于交易结构、代价、时间表及先决条 件)进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可作实。 ...

截至公告日期，各方主体仍就可能交易的具体方案(包括但不限于交易结构、代价、时间表及先决条件) 进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可作实。 格隆汇11月10日丨华检医疗(01931.HK)公布，公司一家于中国境内设立的有限合伙企业，杭州更好智投 管理谘询合伙企业(有限合伙)(该企业由公司下属企业出资设立，并依照中国法律组建及存续)，目前正 在与创业慧康科技股份有限公司("创业慧康")第一大股东葛航筹划创业慧康控制权相关事宜。创业慧康 (股份代号：300451.SZ)为一间于中国注册成立的股份有限公司，其股份于深圳证券交易所创业板上 市。 ...

格隆汇11月10日丨华检医疗(01931.HK)公布，公司一家于中国境内设立的有限合伙企业，杭州更好智投 管理谘询合伙企业(有限合伙)(该企业由公司下属企业出资设立，并依照中国法律组建及存续)，目前正 在与创业慧康科技股份有限公司("创业慧康")第一大股东葛航筹划创业慧康控制权相关事宜。创业慧康 (股份代号：300451.SZ)为一间于中国注册成立的股份有限公司，其股份于深圳证券交易所创业板上 市。 截至公告日期，各方主体仍就可能交易的具体方案(包括但不限于交易结构、代价、时间表及先决条件) 进行论证和磋商。可能交易的最终条款须待相关方进一步谈判并签订正式协议后方可作实。 ...

创业慧康表示，经公司向深交所申请，公司股票自11月10日开市起停牌，预计停牌时间不超过2个交易 日。 北京商报讯（记者 丁宁）11月10日午间，创业慧康（300451）发布公告称，公司第一大股东、持股5% 以上股东葛航正与杭州更好智投管理咨询合伙企业（有限合伙）筹划控制权相关事宜，该事项可能导致 公司将由无实际控制人状态变更为有实际控制人状态。 ...

Core Points - The company is planning a change in control, potentially moving from a state of no actual controller to having one, involving major shareholder Ge Hang and Hangzhou Genghao Zhito Management Consulting Partnership [1] - The company's stock will be suspended from trading starting November 10, 2025, for a period not exceeding two trading days [1] Company Overview - Founded in 1997, the company is one of the early entrants in the medical and health information technology sector in China, focusing on the construction, research, and service innovation of health information systems [1] - The company has implemented nearly 20,000 health information construction projects, serving over 7,000 industry users, with public health projects covering more than 370 districts and counties nationwide, accumulating approximately 300 million resident health records [1] Financial Performance - For the first half of 2025, the company reported total revenue of 577 million yuan, a year-on-year decrease of 20.65% [1] - The net loss attributable to shareholders for the same period was 80.55 million yuan, compared to a loss of 27.37 million yuan in the previous year, indicating an expanded loss [1] Industry Metrics - In the first half of 2025, the internet hospital prescription flow reached 190,000 orders, with a 140% increase in traditional Chinese medicine prescription collaborations [2] - The company has partnered with over 250 commercial insurance institutions and aggregated payment merchants totaling 2,000, with 48 million new transactions and a transaction volume of 8.5 billion yuan [2] - Cloud nursing collaborations involve over 250 institutions, with more than 7,600 nurses and 93,800 orders processed [2]